Mortality, short-term neonatal morbidities and long-term neurodevelopmental outcomes among infants born <29 weeks, by gestational age
| Mortality and short-term morbidities | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mortality | CLD | IVH grade 3 or 4* | ||||||||||
| GA (weeks) | No steroids, <24 h | Complete, >7 days | OR (95% CI) | p V alue | No steroids, <24 h | Complete, >7 days | OR (95% CI) | p Value | No steroids, <24 h | Complete, >7 days | OR (95% CI) | p Value |
| 23 n=99 | 47 (74.6) | 22 (61.1) | 0.54 (0.22 to 1.29) | 0.239 | 15 (23.8) | 13 (36.1) | 1.81 (0.74 to 4.42) | 0.282 | 14/48 (29.2) | 12/33 (36.4) | 1.39 (0.54 to 3.57) | 0.660 |
| 24 n=276 | 71 (60.7) | 70 (44.0) | 0.51 (0.31 to 0.83) | 0.009 | 37 (31.6) | 71 (44.7) | 1.74 (1.06 to 2.88) | 0.039 | 36/101 (35.6) | 25/144 (17.4) | 0.38 (0.21 to 0.69) | 0.002 |
| 25 n=375 | 64 (43.0) | 69 (30.5) | 0.58 (0.38 to 0.90) | 0.019 | 52 (34.9) | 89 (39.4) | 1.21 (0.79 to 1.86) | 0.443 | 40/137 (29.2) | 26/207 (12.6) | 0.35 (0.20 to 0.60) | <0.001 |
| 26 n=521 | 50 (24.8) | 54 (16.9) | 0.62 (0.40 to 0.96) | 0.039 | 60 (29.7) | 147 (46.1) | 2.02 (1.39 to 2.94) | <0.001 | 48/189 (25.4) | 17/306 (5.6) | 0.17 (0.10 to 0.31) | <0.001 |
| 27n=557 | 26 (12.5) | 25 (7.2) | 0.54 (0.30 to 0.96) | 0.050 | 50 (24.00 | 107 (30.7) | 1.40 (0.95 to 2.07) | 0.114 | 26/204 (12.7) | 24/343 (7.0) | 0.52 (0.29 to 0.92) | 0.036 |
| 28 n=716 | 18 (7.1) | 25 (5.4) | 0.75 (0.40 to 1.39) | 0.448 | 38 (15.0) | 82 (17.7) | 1.22 (0.80 to 1.85) | 0.414 | 20/247 (8.1) | 16/453 (3.5) | 0.42 (0.21 to 0.82) | 0.015 |
| Long-term outcomes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mod/severe FD* | Developmental delay −1–2 SD* | Developmental delay −2–3SD* | ||||||||||
| GA (weeks) | No steroids, <24 h | Complete, >7 days | OR (95% CI) | p Value | No steroids, <24 h | Complete, >7 days | OR (95% CI) | p Value | No steroids, <24 h | Complete, >7 days | OR (95% CI) | p Value |
| 23 n=23 | 7 (53.8) | 3 (30.0) | 0.37 (0.06 to 2.09) | 0.402 | 4/10 (40.0) | 1/8 (12.5) | 0.21 (0.02 to 2.48) | 0.451 | 1/10 (10.0) | 1/8 (12.5) | 1.29 (0.07 to 24.38) | >0.999 |
| 24 n=117 | 10 (25.0) | 28 (36.4) | 1.71(0.73 to 4.02) | 0.300 | 3/35 (8.6) | 6/68 (8.8) | 1.03 (0.24 to 4.40) | >0.999 | 4/35 (11.4) | 11/68 (16.2) | 1.50 (0.44 to 5.09) | 0.725 |
| 25 n=206 | 17 (23.0) | 23 (17.4) | 1.41 (0.70 to 2.86) | 0.434 | 5/64 (7.8) | 10/110 (9.1) | 1.18 (0.38 to 3.62) | 0.992 | 10/64 (15.6) | 7/110 (6.4) | 0.37 (0.13 to 1.02) | 0.086 |
| 26 n=301 | 20 (18.5) | 38 (19.7) | 1.08 (0.59 to 1.97) | 0.925 | 8/99 (8.1) | 14/169 (8.3) | 1.03 (0.42 to 2.54) | 0.863 | 6/99 (6.1) | 8/169 (4.7) | 0.77 (0.26 to 2.29) | 0.852 |
| 27 n=365 | 16/120 (13.3) | 27/244 (11.1) | 0.81 (0.42 to 1.57) | 0.647 | 4/102 (3.9) | 14/222 (6.3) | 1.65 (0.53 to 5.14) | 0.542 | 5/102 (4.9) | 7/222 (3.2) | 0.63 (0.20 to 2.04) | 0.628 |
| 28 n=461 | 16 (10.3) | 35 (11.5) | 1.13 (0.61 to 2.12) | 0.812 | 4/139 (2.9) | 11/260 (4.2) | 1.49 (0.47 to 4.77) | 0.689 | 4/139 (2.9) | 4/260 (1.5) | 0.53 (0.13 to 2.14) | 0.577 |
*Denominator is the number of infants examined; data unavailable in some cases.
Data are presented as n (%) (OR, 95%, CI) or median (IQR). No steroid + <24 h steroid infant group set as referent for OR and 95% CI calculation.
CLD, chronic lung disease; FD, functional disability; IVH, intraventricular haemorrhage.